



# GLOBAL CANCER TECHNOLOGY

## PRESS RELEASE

### For Immediate Release

**Contact:**

Kelly O'Connor  
Global Cancer Technology  
Ph: (619) 818-2411  
Fax: (800) 886-3880  
info@globalcancertechnology.com

### **Global Cancer Technology, Inc. Signs Memorandum of Understanding with University of California San Diego Scientists**

AGREEMENT REACHED TO FINALIZE DEVELOPMENT OF A NOVEL METHOD TO LINK A NANOCRYSTAL SCINTILLATOR TO A DRUG TO CREATE A RADIATION ACTIVATABLE PRODRUG

**San Diego, CA, August 28<sup>th</sup>, 2016** – Global Cancer Technology, Inc. announced today that the company has signed a Memorandum of Understanding “MOU” with Scientists from the University of California San Diego to bring to market a unique cancer drug delivery system.

This system functions as a non-toxic and inactive prodrug, and consists of a drug bound to a nanocrystal scintillator. The scintillator is radiosurgically triggered to release the drug at a defined anatomical location and at a specific time.

Dr. Milan Makale, one of the principal inventors of the patented process commented, “we are delighted to partner with Global Cancer Technology, Inc. to help us finance and bring this unique cancer drug delivery method to market”. Dr. Makale further stated “the success of the process will have huge implications in the cancer drug delivery arena”.

Mr. John Clark, the CEO of Global Cancer Technology Inc. stated, “our deep background in the radiosurgery and financial sectors, combined with the advanced research capabilities of the UC San Diego scientists, should insure successful pre-clinical and clinical trials.” Mr. Clark went on to state “this marks the entry of our company into the billion dollar cancer drug delivery market”

Global Cancer Technology, Inc. provides Products, Partnerships and Services to the worldwide medical and oncology market.

---

---

*Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-*

*looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.*